Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Receivables - Other (2017 - 2024)

Historic Receivables - Other for Innate Pharma (IPHA) over the last 8 years, with Q4 2024 value amounting to $770457.3.

  • Innate Pharma's Receivables - Other rose 58853.68% to $770457.3 in Q4 2024 from the same period last year, while for Dec 2024 it was $770457.3, marking a year-over-year increase of 58853.68%. This contributed to the annual value of $780365.9 for FY2024, which is 59366.7% up from last year.
  • As of Q4 2024, Innate Pharma's Receivables - Other stood at $770457.3, which was up 58853.68% from $111897.8 recorded in Q4 2023.
  • In the past 5 years, Innate Pharma's Receivables - Other registered a high of $931192.5 during Q4 2021, and its lowest value of $62235.1 during Q4 2022.
  • For the 5-year period, Innate Pharma's Receivables - Other averaged around $551853.9, with its median value being $770457.3 (2024).
  • Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 9331.66% in 2022, then surged by 58853.68% in 2024.
  • Innate Pharma's Receivables - Other (Quarter) stood at $883486.7 in 2020, then increased by 5.4% to $931192.5 in 2021, then tumbled by 93.32% to $62235.1 in 2022, then skyrocketed by 79.8% to $111897.8 in 2023, then surged by 588.54% to $770457.3 in 2024.
  • Its Receivables - Other stands at $770457.3 for Q4 2024, versus $111897.8 for Q4 2023 and $62235.1 for Q4 2022.